Email ID
Password
Policy & Regulation - Regulation
JOB OF THE WEEK Promote your vacancy here
Shares in the US company MannKind dropped by 25% earlier this week as investors reacted to a US FDA complete response letter for its inhaled rapid-acting insulin product Afrezza (formerly Afresa). The product is awaiting a decision for the ...
GW Pharmaceuticals is anticipating regulatory approvals of its cannabis extract CB1 agonist Sativex Oromucosal Spray (nabiximols) in the UK and Spain during the second quarter for the treatment of symptoms of spasticity in multiple ...
Grindeks has signed an agreement for the development of a structural analogue of its leading product, the cardiovascular Mildronate (meldonium), with the Latvian institute of organic synthesis (OSI) where the original product was discovered. The ...
The MEP responsible for guiding the controversial patient information proposal through the European Parliament says he is not prepared to see it derailed by opposition from member state ministers and certain political groupings in parliament. ...
Janssen-Cilag (Johnson & Johnson) has requested a re-examination of the negative opinion adopted by the EU's CHMP for the filing of Basilea Pharmaceutica 's antibiotic Zeftera (ceftobiprole) for the treatment of complicated skin and soft tissue ...
 
Hospitals' failure to pay pharmaceutical companies and newly announced price cuts are just some of the challenges facing the sector in Greece, Elizabeth Sukkar, Scrip's world editor, discovers. ...
The pharmaceutical industry has long eyed Turkey as one of its key emerging markets, but recent government action, which could see medicine access delayed by years, is giving it a wake-up call, ...
US agencies are making inroads in the use of comparative effectiveness research to support more robust decision-making. Observational studies are an emerging force in this area and promise to ...
 
Jeff George took over as head of Sandoz, Novartis's generics business, in late 2008. With a big push in emerging markets, a leadership position in biosimilars and an expanded focus on injectables, he ...
Developing relationships with medicine regulators in China and India is just one of the challenges facing Emer Cooke, the international face of the European Medicines Agency (EMA), Scrip's Elizabeth ...
Many pharmaceutical and biotech companies devote themselves to the discovery and development of novel drugs for unmet medical needs. However, with R&D costs and regulatory hurdles multiplying, and ...
 
Private investments began 2010 in a much more positive fashion than at the start of 2009, but were still down on the strong finish to last year, a Scrip analysis has found. A total of 15 companies raised $286.7 million, 17% lower than December. ...
Logos are said to be an important part of an organisation's branding. Really good logos contribute to an organisation's visibility, credibility and memorability, so say branding experts. The logo of the most famous of the medicines regulators, the ...
GlaxoSmithKline will enter unknown regulatory waters when it eventually comes to seek approval of its paediatric malaria vaccine, RTS,S, the most advanced in development for this disease. The parasite kills more than 800,000 people every year, the ...
 
Background: The renin-angiotensin-aldosterone system (RAAS) is essential for the regulation of blood pressure and may play a critical role in the pathogenesis of cardiovascular diseases. A strong rationale suggests a more efficient control of RAAS ...
Cetuximab is a human/mouse chimeric monoclonal antibody that binds to the EGF receptor, competitively inhibiting ligand binding, and inducing receptor dimerization and downregulation. Cetuximab has been active in multiple tumors, including ...
This meeting, jointly sponsored by the FDA, Drug Information Association and Heart Rhythm Society, examined crucial issues on nonclinical and clinical evaluation of the potential of new drugs to prolong the QT interval of an electrocardiogram (ECG). ...
 
COMPANY/ORGANISATION
CONDITION
GEOGRAPHY
DRUG
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36